Developer docs
API playgroundTry for free, no card

Search company profiles

Viralgen

Full company profile

uuid00071kh

Namestring
Viralgen
Legal namestring
Viralgen
Websiteurl
viralgenvc.com
Company typeenum
Private
Founded yearint
2017
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersDonostia-san Sebastián, Spain
HQ citystring
Donostia-san Sebastián
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AAV gene therapy manufacturing, contract development manufacturing, viral vector production, cGMP biomanufacturing, gene therapy CDMO
Industry4 codes
PRIMARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAAKAD
Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Contract Manufacturing (CDMO)
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development and Manufacturing Services (CDMO)
TypeProfessional Services
Description

Viralgen generates revenue through providing end-to-end AAV gene therapy manufacturing services including process development, early and late phase clinical production, and commercial manufacturing. Services are delivered through fixed-cost packages and all-inclusive pricing models for pharmaceutical and biotech clients.

viralgen.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Aava™ Platform
Description

Viralgen's proprietary manufacturing platform built on the AskBio Pro10™ suspension cell line for high-yield scalable AAV manufacturing across all serotypes.

viralgen.com
Core offering1 text field

Viralgen is a Contract Development and Manufacturing Organization (CDMO) that provides end-to-end cGMP manufacturing of adeno-associated virus (AAV) vectors for gene therapy developers. Its offering is anchored by the proprietary Aava™ Platform built on the AskBio Pro10™ HEK293 suspension cell line, delivering scalable production across all AAV serotypes from 100ml to 2,000L, supported by integrated QC/release testing and regulatory expertise for IND, IMPD, BLA and CMC filings.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 100% success rate for IND/IMPD dossiers submitted
+4 more records
Product overview1 text field

Viralgen is a Contract Development and Manufacturing Organization (CDMO) specializing exclusively in AAV-based gene therapy manufacturing. The company's offering centers on the Aava™ Platform, a proprietary manufacturing platform built on the AskBio Pro10™ suspension cell line, which delivers high-yield scalable production across all AAV serotypes from 100ml to 2,000L. Viralgen provides end-to-end services spanning Process Development (construct optimization and platform fit), Early Phase Production (feasibility studies and early clinical material), Late Phase Production (large-scale clinical and commercial manufacturing), and integrated QC/release support with over 85% of methods performed in-house, plus globally compliant regulatory support for CMC filings. The company operates the world's largest AAV-dedicated facility (343,255 sq ft) in San Sebastián, Spain.

Product and service5 records
1Aava™ Platform
CategoryManufacturing Platform
Description

Proprietary AAV manufacturing platform built upon the AskBio Pro10™ HEK293 suspension cell line, enabling high-yield scalable manufacturing across all AAV serotypes from 100ml to 2,000L for gene therapy developers.

2Process Development
CategoryCDMO Service
Description

Early-stage development services including construct optimization and platform fit assessment to guide gene therapy development decisions for pharmaceutical and biotech clients.

3Early Phase Production
CategoryCDMO Service
Description

Clinical trial material production for early-phase studies, including small feasibility studies and GMP-compliant manufacturing for gene therapy programs.

4Late Phase Production
CategoryCDMO Service
Description

Late-stage clinical and commercial manufacturing services including large-scale production, purification, and fill-finish across broad format ranges for gene therapy programs.

5Plasmid DNA Production
CategoryCDMO Service
Description

Plasmid DNA production provided as part of end-to-end AAV manufacturing support, from construct optimization through large-scale production.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-11
Description

Myrtelle presented clinical trial data for its MYR-101 gene therapy program for Canavan disease at ASGCT 2026, with CEO Adrian Stecyk speaking at a Viralgen-hosted symposium. Viralgen provides manufacturing support for Myrtelle's gene therapy program, which holds an exclusive worldwide licensing agreement with Pfizer Inc. and is participating in the FDA START Pilot Program.

2Elaaj Bio
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-05
Description

Viralgen partnered with Elaaj Bio to advance ELJ-101, a preclinical-stage investigational gene therapy for CDKL5 Deficiency Disorder (CDD), a rare pediatric neurological condition. Viralgen provides AAV manufacturing expertise including process development, optimization, and scale-up activities. Initial development work has demonstrated technical feasibility, with the collaboration aiming to initiate the first clinical trial in early 2027. Elaaj Bio is a wholly-owned subsidiary of the UK-based Loulou Foundation.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-20
Description

AskBio (parent company) introduced its proprietary commercially ready manufacturing process to supply ametefgene parvec (AB-1005) for the REGENERATE-PD Phase II clinical trial for Parkinson's disease, with drug product manufactured at Viralgen's commercial facility in Spain using next-generation large-scale suspension process. The trial is enrolling across Germany, Poland, UK, and US.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-17
Description

Viralgen and Apertura Gene Therapy announced a strategic manufacturing collaboration to produce TfR1 CapX, a novel AAV capsid designed to cross the blood-brain barrier for treating central nervous system diseases. The partnership enables Apertura's licensees to access TfR1 CapX plasmids through Viralgen's integrated AAV manufacturing platform, with multiple partner programs expected to advance into clinical trials. Viralgen has already scaled up manufacturing and is ready to support clinical development.

Strategic tierCoreTypeOthersAnnounced on2025-10-13
Description

Bayer AG, through its subsidiary Viralgen, is developing cell and gene therapies (CGT) aimed at treating diseases such as Parkinson's, oncology, cardiovascular, and rare conditions. Bayer acquired AskBio (Viralgen's parent company) in fall 2020 for up to $4 billion and is expanding its pipeline and manufacturing capacity.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Yposkesi
TypeDirect peer
Description

Yposkesi is a European AAV and lentiviral vector CDMO located in France, serving gene therapy developers with cGMP manufacturing. Its AAV focus and European footprint make it a direct competitor to Viralgen in the EMEA region.

TypeBroad incumbent
Description

Catalent, recently acquired by Novo Holdings, offers viral vector manufacturing including AAV alongside a broad biologics CDMO portfolio. It is a major incumbent competitor for gene therapy manufacturing services.

TypeEmerging player
Description

Genezen is a US-based viral vector CDMO focused on lentiviral and AAV manufacturing for gene and cell therapy developers. It is an emerging specialist competitor with overlapping AAV capabilities and customer base.

TypeEmerging player
Description

Centre for Breakthrough Medicines is a US-based cell and gene therapy CDMO offering AAV and other viral vector manufacturing. It is an emerging player competing for similar gene therapy developer clients.

TypeDirect peer
Description

Biovian is a European CDMO offering AAV, lentiviral, and other viral vector manufacturing services. It is a direct peer in the AAV gene therapy manufacturing space, particularly for European biotech customers.

TypeBroad incumbent
Description

AGC Biologics provides viral vector and cell therapy CDMO services as part of its broader biologics manufacturing offerings. It is a relevant incumbent peer for AAV gene therapy manufacturing contracts.

TypeDirect peer
Description

Forge Biologics is a US-based CDMO specializing in AAV and lentiviral vector manufacturing with scalable cGMP production. It is one of the most directly comparable AAV-focused CDMOs to Viralgen, competing for the same gene therapy developer customers.

TypeBroad incumbent
Description

Lonza is one of the largest global CDMOs with a substantial viral vector and cell therapy manufacturing offering across multiple sites. It competes with Viralgen for AAV gene therapy manufacturing contracts as part of a broader biologics portfolio.

TypeBroad incumbent
Description

Charles River Laboratories offers viral vector and gene therapy CDMO services including AAV manufacturing as part of its broader discovery and manufacturing portfolio. It is a relevant incumbent peer for gene therapy manufacturing.

TypeBroad incumbent
Description

Thermo Fisher Scientific provides viral vector manufacturing services through its pharma services division as part of a massive global CDMO portfolio. It competes with Viralgen for AAV contracts through its Patheon and Brammer Bio operations.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Viralgen

Biopharmaceutical Contract Manufacturing (CDMO)viralgenvc.com

Viralgen firmographics

Firmographics
Name
Viralgen
Legal name
Viralgen
Website
https://viralgenvc.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
251–500 employees
Ownership category
akta.pro rank

Viralgen industry classification

Industry
Product category
Biopharmaceutical Contract Manufacturing (CDMO)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAAKAD
Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • AAV gene therapy manufacturing
  • Contract development manufacturing
  • Viral vector production
  • CGMP biomanufacturing
  • Gene therapy CDMO

Where Viralgen is headquartered

Location

Headquarters

HQ city
Donostia-san Sebastián
HQ country
Spain
HQ region
Europe

Offices2 records

Markets served

Viralgen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Development and Manufacturing Services (CDMO): Viralgen generates revenue through providing end-to-end AAV gene therapy manufacturing services including process development, early and late phase clinical production, and commercial manufacturing. Services are delivered through fixed-cost packages and all-inclusive pricing models for pharmaceutical and biotech clients.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Viralgen product offering

Product offering

Core offering

Viralgen is a Contract Development and Manufacturing Organization (CDMO) that provides end-to-end cGMP manufacturing of adeno-associated virus (AAV) vectors for gene therapy developers. Its offering is anchored by the proprietary Aava™ Platform built on the AskBio Pro10™ HEK293 suspension cell line, delivering scalable production across all AAV serotypes from 100ml to 2,000L, supported by integrated QC/release testing and regulatory expertise for IND, IMPD, BLA and CMC filings.

Product overview

Viralgen is a Contract Development and Manufacturing Organization (CDMO) specializing exclusively in AAV-based gene therapy manufacturing. The company's offering centers on the Aava™ Platform, a proprietary manufacturing platform built on the AskBio Pro10™ suspension cell line, which delivers high-yield scalable production across all AAV serotypes from 100ml to 2,000L. Viralgen provides end-to-end services spanning Process Development (construct optimization and platform fit), Early Phase Production (feasibility studies and early clinical material), Late Phase Production (large-scale clinical and commercial manufacturing), and integrated QC/release support with over 85% of methods performed in-house, plus globally compliant regulatory support for CMC filings. The company operates the world's largest AAV-dedicated facility (343,255 sq ft) in San Sebastián, Spain.

Differentiator

Problem solved

Functional benefit

Brands

  • Aava™ Platform: Viralgen's proprietary manufacturing platform built on the AskBio Pro10™ suspension cell line for high-yield scalable AAV manufacturing across all serotypes.

Products and services

  • Aava™ Platform Proprietary AAV manufacturing platform built upon the AskBio Pro10™ HEK293 suspension cell line, enabling high-yield scalable manufacturing across all AAV serotypes from 100ml to 2,000L for gene therapy developers.
  • Process Development Early-stage development services including construct optimization and platform fit assessment to guide gene therapy development decisions for pharmaceutical and biotech clients.
  • Early Phase Production Clinical trial material production for early-phase studies, including small feasibility studies and GMP-compliant manufacturing for gene therapy programs.
  • Late Phase Production Late-stage clinical and commercial manufacturing services including large-scale production, purification, and fill-finish across broad format ranges for gene therapy programs.
  • Plasmid DNA Production Plasmid DNA production provided as part of end-to-end AAV manufacturing support, from construct optimization through large-scale production.

Quantifiable outcome

  • 100% success rate for IND/IMPD dossiers submitted
  • +4 more outcomes

Companies that use Viralgen

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Viralgen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Viralgen partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • MyrtellecoreStrategic or Co-development Partner · 11 May 2026Myrtelle presented clinical trial data for its MYR-101 gene therapy program for Canavan disease at ASGCT 2026, with CEO Adrian Stecyk speaking at a Viralgen-hosted symposium. Viralgen provides manufacturing support for Myrtelle's gene therapy program, which holds an exclusive worldwide licensing agreement with Pfizer Inc. and is participating in the FDA START Pilot Program.
  • Elaaj BiocoreStrategic or Co-development Partner · 5 May 2026Viralgen partnered with Elaaj Bio to advance ELJ-101, a preclinical-stage investigational gene therapy for CDKL5 Deficiency Disorder (CDD), a rare pediatric neurological condition. Viralgen provides AAV manufacturing expertise including process development, optimization, and scale-up activities. Initial development work has demonstrated technical feasibility, with the collaboration aiming to initiate the first clinical trial in early 2027. Elaaj Bio is a wholly-owned subsidiary of the UK-based Loulou Foundation.
  • AskBiocoreStrategic or Co-development Partner · 20 April 2026AskBio (parent company) introduced its proprietary commercially ready manufacturing process to supply ametefgene parvec (AB-1005) for the REGENERATE-PD Phase II clinical trial for Parkinson's disease, with drug product manufactured at Viralgen's commercial facility in Spain using next-generation large-scale suspension process. The trial is enrolling across Germany, Poland, UK, and US.
  • Apertura Gene TherapycoreStrategic or Co-development Partner · 17 March 2026Viralgen and Apertura Gene Therapy announced a strategic manufacturing collaboration to produce TfR1 CapX, a novel AAV capsid designed to cross the blood-brain barrier for treating central nervous system diseases. The partnership enables Apertura's licensees to access TfR1 CapX plasmids through Viralgen's integrated AAV manufacturing platform, with multiple partner programs expected to advance into clinical trials. Viralgen has already scaled up manufacturing and is ready to support clinical development.
  • Bayer AGcoreOthers · 13 October 2025Bayer AG, through its subsidiary Viralgen, is developing cell and gene therapies (CGT) aimed at treating diseases such as Parkinson's, oncology, cardiovascular, and rare conditions. Bayer acquired AskBio (Viralgen's parent company) in fall 2020 for up to $4 billion and is expanding its pipeline and manufacturing capacity.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Viralgen competitors and assessment

Company assessment

Direct peers

  • Yposkesi: Yposkesi is a European AAV and lentiviral vector CDMO located in France, serving gene therapy developers with cGMP manufacturing. Its AAV focus and European footprint make it a direct competitor to Viralgen in the EMEA region.
  • Biovian: Biovian is a European CDMO offering AAV, lentiviral, and other viral vector manufacturing services. It is a direct peer in the AAV gene therapy manufacturing space, particularly for European biotech customers.
  • Forge Biologics: Forge Biologics is a US-based CDMO specializing in AAV and lentiviral vector manufacturing with scalable cGMP production. It is one of the most directly comparable AAV-focused CDMOs to Viralgen, competing for the same gene therapy developer customers.

Broad incumbents

  • Catalent (Novo Holdings): Catalent, recently acquired by Novo Holdings, offers viral vector manufacturing including AAV alongside a broad biologics CDMO portfolio. It is a major incumbent competitor for gene therapy manufacturing services.
  • AGC Biologics: AGC Biologics provides viral vector and cell therapy CDMO services as part of its broader biologics manufacturing offerings. It is a relevant incumbent peer for AAV gene therapy manufacturing contracts.
  • Lonza (Cell & Gene Technologies): Lonza is one of the largest global CDMOs with a substantial viral vector and cell therapy manufacturing offering across multiple sites. It competes with Viralgen for AAV gene therapy manufacturing contracts as part of a broader biologics portfolio.
  • Charles River Laboratories (Viral Vector): Charles River Laboratories offers viral vector and gene therapy CDMO services including AAV manufacturing as part of its broader discovery and manufacturing portfolio. It is a relevant incumbent peer for gene therapy manufacturing.
  • Thermo Fisher Scientific (Viral Vector Services): Thermo Fisher Scientific provides viral vector manufacturing services through its pharma services division as part of a massive global CDMO portfolio. It competes with Viralgen for AAV contracts through its Patheon and Brammer Bio operations.

Emerging players

  • Genezen: Genezen is a US-based viral vector CDMO focused on lentiviral and AAV manufacturing for gene and cell therapy developers. It is an emerging specialist competitor with overlapping AAV capabilities and customer base.
  • Centre for Breakthrough Medicines: Centre for Breakthrough Medicines is a US-based cell and gene therapy CDMO offering AAV and other viral vector manufacturing. It is an emerging player competing for similar gene therapy developer clients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Viralgen social profiles

Digital presence

Viralgen compliance and trust

Trust signal

Compliance1 record

Viralgen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Viralgen leadership team

Management profile

Number of profiles

Viralgen funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Viralgen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Viralgen

What does Viralgen do?

Viralgen is a Contract Development and Manufacturing Organization (CDMO) that provides end-to-end cGMP manufacturing of adeno-associated virus (AAV) vectors for gene therapy developers. Its offering is anchored by the proprietary Aava™ Platform built on the AskBio Pro10™ HEK293 suspension cell line, delivering scalable production across all AAV serotypes from 100ml to 2,000L, supported by integrated QC/release testing and regulatory expertise for IND, IMPD, BLA and CMC filings.

Is Viralgen a public or private company?

Viralgen is a private company. It is classified as corporate owned and is currently operating.

When was Viralgen founded?

Viralgen was founded in 2017. It employs 251 to 500 people.

Where is Viralgen based?

Viralgen is headquartered in Donostia-san Sebastián, Spain, in the Europe region.

How does Viralgen make money?

One revenue line is on record: contract Development and Manufacturing Services (CDMO).

Who are Viralgen's main competitors?

Direct peers on record are Yposkesi, Biovian and Forge Biologics. Broad incumbents are Catalent (Novo Holdings), AGC Biologics, Lonza (Cell & Gene Technologies), Charles River Laboratories (Viral Vector) and Thermo Fisher Scientific (Viral Vector Services). Emerging players are Genezen and Centre for Breakthrough Medicines.

Does Viralgen have an API?

No public API is recorded for Viralgen.

What industry is Viralgen in?

Viralgen's product category is Biopharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing), with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AktienViralgen kündigt geplante CEO-Nachfolge anViralgen announced that CEO Jimmy Vanhove will move to lead Bayer's US pharmaceutical product supply network, with Angela Ochoa Chico succeeding him as CEO effective January 1, 2027. Vanhove's four-year tenure grew the company into a leading AAV CDMO with over 70 global customers.PR NewswireViralgen kündigt geplante CEO-Nachfolge anViralgen announced that CEO Jimmy Vanhove will transition to lead Bayer's US pharmaceutical product supply network, with Angela Ochoa Chico succeeding him as CEO effective January 1, 2027. Vanhove will join the Product Supply Leadership Team, while Ochoa Chico brings nearly 20 years of pharmaceutical operations experience.PR NewswireViralgen anuncia la sucesión prevista de su consejero delegadoViralgen announced that Jimmy Vanhove will take a new role leading Bayer's US pharmaceutical supply chain, while Angela Ochoa Chico will succeed him as CEO, effective January 1, 2027. Vanhove will join Bayer's supply chain leadership team, and Ochoa Chico brings over 20 years of pharmaceutical operations experience.PR NewswireViralgen annonce un plan de succession pour son PDGViralgen announced that CEO Jimmy Vanhove will move to a new role leading Bayer's US pharmaceutical supply chain, with Angela Ochoa Chico succeeding him as CEO on January 1, 2027. Under Vanhove, Viralgen grew from an emerging CDMO to a market leader in AAV gene therapies, serving over 70 clients.PR NewswireViralgen announces planned CEO successionViralgen announced CEO Jimmy Vanhove will transition to a new role leading Bayer's U.S. Pharmaceutical Product Supply Network, with Angela Ochoa Chico appointed as CEO effective January 1, 2027. Vanhove led the company for four years, growing it into a market-leading AAV CDMO with over 70 customers. Ochoa Chico brings nearly 20 years of pharmaceutical operations experience.PR NewswireViralgen announces planned CEO successionViralgen announced CEO Jimmy Vanhove will transition to a new role leading Bayer's U.S. Pharmaceutical Product Supply Network, with Angela Ochoa Chico appointed as his successor, effective January 1, 2027. Vanhove led the company for four years, growing it into a market-leading AAV CDMO with over 70 customers. Ochoa Chico brings nearly 20 years of pharmaceutical operations experience.PharmaTimesEpilepsyGTx and Viralgen partner to scale AAV manufacturing for EPY201EpilepsyGTx and Viralgen announced a partnership to scale AAV manufacturing for EPY201, a gene therapy for focal refractory epilepsy. The collaboration uses Viralgen's Aava platform, which has produced 1,500 AAV batches, to support first-in-human trials. The therapy aims to reduce neuronal hyperexcitability locally without brain resection.News-MedicalEpilepsyGTx and Viralgen collaborate to advance AAV gene therapy program for epilepsy ahead of first-in-human trialEpilepsyGTx and Viralgen announced a partnership to produce EPY201, a gene therapy for focal refractory epilepsy, ahead of first-in-human trials. Viralgen will use its Aava platform, which has produced 1,500 AAV batches, to scale manufacturing. The therapy aims to reduce neuronal hyperexcitability locally without brain resection.PR NewswireEpilepsyGTx und Viralgen arbeiten gemeinsam daran, das AAV-Gentherapieprogramm zur Behandlung von Epilepsie im Vorfeld der ersten klinischen Studie am Menschen voranzutreibenEpilepsyGTx and Viralgen announced a partnership to scale production of EPY201, an AAV-based gene therapy for focal refractory epilepsy, ahead of its first human clinical trials. Viralgen will use its Aava platform, which has produced 1,500 AAV batches, to support manufacturing. The therapy targets about 10 million patients worldwide, with trials planned in early 2027.MorningstarEpilepsyGTx and Viralgen collaborate to advance AAV gene therapy programme for epilepsy ahead of first-in-human trialEpilepsyGTx and Viralgen announced a partnership to support production of EPY201, an AAV gene therapy for focal refractory epilepsy, ahead of first-in-human trials. Viralgen will use its Aava platform, which has produced 1,500 AAV batches, to scale manufacturing. The therapy targets the seizure focus via intraparenchymal delivery, with trials planned in the first half of 2027.